BRIEF-Marsh Mclennan Agency Acquires Olympic Insurance Agency-March 2024-www.financetom.com

BRIEF-Marsh Mclennan Agency Acquires Olympic Insurance Agency

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Marsh Mclennan Agency Acquires Olympic Insurance Agency

Aug 1, 2025 10:10 AM

Aug 1 (Reuters) - Marsh & McLennan Companies Inc ( MMC )

* MARSH MCLENNAN AGENCY ACQUIRES OLYMPIC INSURANCE AGENCY

* MARSH & MCLENNAN COMPANIES INC ( MMC ) - TERMS OF ACQUISITION NOT

DISCLOSED

Previous page： BJ's Restaurants Chief Growth, Innovation Officer Steps Down Next page： Cargurus Insider Sold Shares Worth $3,783,520, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BJ's Restaurants Chief Growth, Innovation Officer Steps Down

Jan 21, 2025

05:42 PM EST, 01/21/2025 (MT Newswires) -- BJ's Restaurants (BJRI) said Tuesday that Putnam Shin stepped down as chief growth and innovation officer. The move went into effect Jan. 17, according to a regulatory filing. ...

Cargurus Insider Sold Shares Worth $3,783,520, According to a Recent SEC Filing

Jan 21, 2025

05:41 PM EST, 01/21/2025 (MT Newswires) -- Langley Steinert, 10% Owner, Director, Executive Chair, on January 16, 2025, sold 100,898 shares in Cargurus ( CARG ) for $3,783,520. Following the Form 4 filing with the SEC, Steinert has control over a total of 839,340 shares of the company, with 798,056 shares held directly and 41,284 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1494259/000112760225001639/xslF345X05/form4.xml...

Xilio Therapeutics Phase 2 Study of Vilastobart Plus Atezolizumab Demonstrates 27% Response Rate in Colorectal Cancer

Jan 21, 2025

05:42 PM EST, 01/21/2025 (MT Newswires) -- Xilio Therapeutics ( XLO ) said late Tuesday that initial data from a phase 2 study of vilastobart in combination with atezolizumab to treat metastatic microsatellite stable colorectal cancer showed a 27% preliminary response rate in patients without liver metastases. The drug combination also reduced levels of carcinoembryonic antigen and circulating tumor DNA...

BRIEF-Voyager Technologies Submits Confidential Registration Statement For Proposed IPO

Jan 21, 2025

Jan 21 (Reuters) - Voyager Technologies: * VOYAGER SUBMITS CONFIDENTIAL REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING ...